Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. UroGen Pharma Ltd.
  6. News
  7. Summary
    URGN   IL0011407140

UROGEN PHARMA LTD.

(URGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HC Wainwright Adjusts UroGen Pharma's Price Target to $34 From $50, Reiterates Buy Rating

01/18/2022 | 10:43am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about UROGEN PHARMA LTD.
05/18UroGen Pharma to Present at Upcoming Investor Conferences
BU
05/17UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Off..
AQ
05/16UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Off..
BU
05/16UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association..
AQ
05/13UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association..
BU
05/10TRANSCRIPT : UroGen Pharma Ltd., Q1 2022 Earnings Call, May 10, 2022
CI
05/10UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Develop..
BU
05/10UROGEN PHARMA LTD. Management's Discussion and Analysis of Financial Condition and Res..
AQ
05/10UroGen Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Loss $-1.25, vs. Street Est of $-1.25
MT
More news
Analyst Recommendations on UROGEN PHARMA LTD.
More recommendations
Financials (USD)
Sales 2022 76,8 M - -
Net income 2022 -114 M - -
Net cash 2022 31,0 M - -
P/E ratio 2022 -1,14x
Yield 2022 -
Capitalization 125 M 125 M -
EV / Sales 2022 1,22x
EV / Sales 2023 0,81x
Nbr of Employees 192
Free-Float 91,1%
Chart UROGEN PHARMA LTD.
Duration : Period :
UroGen Pharma Ltd. Technical Analysis Chart | URGN | IL0011407140 | MarketScreener
Technical analysis trends UROGEN PHARMA LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 5,51 $
Average target price 24,33 $
Spread / Average Target 342%
EPS Revisions
Managers and Directors
Elizabeth Barrett President, Chief Executive Officer & Director
Dong Kim Chief Financial & Accounting Officer
Arie S. Belldegrun Chairman
Moran Mieron Director-Research & Pre-Clinical Affairs
Mark P. Schoenberg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
UROGEN PHARMA LTD.-42.06%125
GILEAD SCIENCES, INC.-12.33%79 850
REGENERON PHARMACEUTICALS, INC.7.98%73 473
VERTEX PHARMACEUTICALS22.20%68 632
WUXI APPTEC CO., LTD.-17.77%42 378
BIONTECH SE-36.69%39 666